Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer

Dong Wook Kim, Hak Choy

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


There has been a surge of interest in the translation of discoveries in molecular biology into clinically relevant therapies in the field of hematology/oncology. The epidermal growth factor receptor (EGFR) has been a molecular target of significant interest and investigation, and preclinical and clinical studies support a role for targeted therapy in a variety of cancers, including non-small-cell lung cancer (NSCLC) via compounds that specifically inhibit EGFR. ZD1839, IMC-C225, and OSI-774 are the most clinically developed of these compounds. Interestingly, preclinical studies have demonstrated that EGFR inhibitors may have radiation-sensitizing properties, as well as increased cytotoxic activity in combination with chemotherapeutic agents, suggesting a potential role for EGFR inhibitors as an adjunct to the current combined-modality approach for therapy of Stage III NSCLC. Therefore, clinical trials have been proposed and initiated to address the issue of determining the impact of the addition of EGFR inhibitors to the standard combined-modality regimen (chemotherapy/radiation therapy ± surgery) for Stage III NSCLC. This article reviews preclinical and clinical data supporting the role for EGFR inhibitors alone or in combination with chemotherapy/radiation therapy for locally advanced NSCLC. Also, it will provide an overview of ongoing and proposed clinical studies investigating the potential role for EGFR inhibitors in Stage III NSCLC.

Original languageEnglish (US)
Pages (from-to)S11-S20
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number2 SUPPL.
StatePublished - Jun 2004


  • Combined-modality treatment
  • Epidermal growth factor receptor (EGFR)
  • Non-small-cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this